RIG-I Enhances Interferon-α Response by Promoting Antiviral Protein Expression in Patients with Chronic Hepatitis B. Issue 7 (October 2018)
- Record Type:
- Journal Article
- Title:
- RIG-I Enhances Interferon-α Response by Promoting Antiviral Protein Expression in Patients with Chronic Hepatitis B. Issue 7 (October 2018)
- Main Title:
- RIG-I Enhances Interferon-α Response by Promoting Antiviral Protein Expression in Patients with Chronic Hepatitis B
- Authors:
- Wu, Shu
Lin, Jinpiao
Fu, Ya
Ou, Qishui - Abstract:
- Background: Interferon (IFN)-α is widely used for the treatment of chronic hepatitis B (CHB) infection due to the high rate of hepatitis B surface antigen (HBsAg) seroconversion. However, IFN-α treatment has a number of side effects. Thus, identification of molecular biomarkers to predict IFN-α therapeutic effect would be useful in the clinic. In this study, we aimed to investigate the role of retinoic acid-inducible gene-I (RIG-I) in prediction of IFN-α curative effect of CHB patients. Methods: A total of 65 CHB patients treated with pegylated IFN-α weekly for 48 weeks were enrolled. Realtime PCR was performed for detection of RIG-I and IFN-stimulated gene (ISG) expression. In vitro, the HepG2 cells were transfected with siRNA and levels of RIG-I and anti-HBV proteins were detected by western blot. The P -values were calculated in SPSS 18.0. The statistical significance level was accepted as P <0.05. Results: In this study, we found RIG-I expression in peripheral blood mononuclear cells was higher in responder than non-responder CHB patients treated with IFN-α therapy. In HBV-transfected HepG2 and Huh7 cells, RIG-I enhanced IFN-α response by promoting anti-HBV protein expression such as double-stranded RNA-dependent protein kinase (PKR), oligoadenylate synthetase (OAS), adenosine deaminase (ADAR1) and Mx protein. Knocking down of RIG-I could downregulate the expression of these proteins. Inhibited RIG-I expression by RIG-I siRNA deceased STAT1 phosphorylation. Conclusions:Background: Interferon (IFN)-α is widely used for the treatment of chronic hepatitis B (CHB) infection due to the high rate of hepatitis B surface antigen (HBsAg) seroconversion. However, IFN-α treatment has a number of side effects. Thus, identification of molecular biomarkers to predict IFN-α therapeutic effect would be useful in the clinic. In this study, we aimed to investigate the role of retinoic acid-inducible gene-I (RIG-I) in prediction of IFN-α curative effect of CHB patients. Methods: A total of 65 CHB patients treated with pegylated IFN-α weekly for 48 weeks were enrolled. Realtime PCR was performed for detection of RIG-I and IFN-stimulated gene (ISG) expression. In vitro, the HepG2 cells were transfected with siRNA and levels of RIG-I and anti-HBV proteins were detected by western blot. The P -values were calculated in SPSS 18.0. The statistical significance level was accepted as P <0.05. Results: In this study, we found RIG-I expression in peripheral blood mononuclear cells was higher in responder than non-responder CHB patients treated with IFN-α therapy. In HBV-transfected HepG2 and Huh7 cells, RIG-I enhanced IFN-α response by promoting anti-HBV protein expression such as double-stranded RNA-dependent protein kinase (PKR), oligoadenylate synthetase (OAS), adenosine deaminase (ADAR1) and Mx protein. Knocking down of RIG-I could downregulate the expression of these proteins. Inhibited RIG-I expression by RIG-I siRNA deceased STAT1 phosphorylation. Conclusions: Our results revealed RIG-I enhanced IFN-α response by promoting antiviral protein expression via the STAT1 pathway. RIG-I may be a new predictive factor for prediction of IFN-α efficacy in CHB patients. … (more)
- Is Part Of:
- Antiviral therapy. Volume 23:Issue 7(2018)
- Journal:
- Antiviral therapy
- Issue:
- Volume 23:Issue 7(2018)
- Issue Display:
- Volume 23, Issue 7 (2018)
- Year:
- 2018
- Volume:
- 23
- Issue:
- 7
- Issue Sort Value:
- 2018-0023-0007-0000
- Page Start:
- 575
- Page End:
- 583
- Publication Date:
- 2018-10
- Subjects:
- Antiviral agents -- Periodicals
Antiviral Agents -- therapeutic use
Virus Diseases -- therapy
Viruses -- drug effects
Antiviral agents
Periodical
Electronic journals
Periodicals
616.9106 - Journal URLs:
- http://www.intmedpress.com/General/showSectionSub.cfm?SectionID=2&SectionSubID=1&SectionSubSubID=1 ↗
http://www.uk.sagepub.com/home.nav ↗ - DOI:
- 10.3851/IMP3239 ↗
- Languages:
- English
- ISSNs:
- 1359-6535
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 17229.xml